
















Esophageal Oncology group : Treatment map Feb.2022.

Subject (UICC 8th)	Standard treatment in Japan	Trials ongoing or follow up
Stage I (N0)	<p>Endoscopic resection (ESD/EMR) + CRT</p> <p>Esophagectomy¹⁾ </p> <p>JCOG0502 Concurrent CRT (CF-RT⁴⁾) </p>	<p>JCOG1904 CRT: IFI⁵⁾ vs. ENI⁶⁾ 2020/03~ Ongoing </p> <p>JCOG1409 (Neo CF²⁾/DCF³⁾ + Esophagectomy¹⁾: Open vs. Thoracoscopic esophagectomy¹⁾ 2015/5~ On going </p> <p>JCOG1804E Neo CF²⁾ or Neo DCF³⁾ or Neo FLOT⁷⁾ +Nivolumab +Esophagectomy¹⁾ 2019/3~ Ongoing </p>
Stage I (N1)	<p> JCOG1109 Neoadjuvant chemotherapy (Neo DCF³⁾) + Esophagectomy¹⁾</p> <p> CheckMate577 Adjuvant Nivolumab (Neo CRT + Esophagectomy)</p> <p> JCOG0909 Concurrent CRT (CF-RT⁴⁾) (+Salvage esophagectomy or endoscopic resection)</p>	
Stage II		
Stage III		
T4a/M1LYM Resectable	<p>Neoadjuvant chemotherapy + Esophagectomy¹⁾ </p> <p>Concurrent CRT </p>	<p>JCOG1510 Concurrent CRT vs. Induction DCF³⁾ + Concurrent CRT or Esophagectomy¹⁾ 2018/2~ Ongoing </p>
T4b/M1LYM Unresectable	<p>Concurrent CRT JCOG9516, JCOG9908, JCOG0303, KROSG0101 </p>	
Stage IVB	<p>1st line chemotherapy: KEYNOTE590 CF²⁾ + Pembrolizumab </p> <p>2nd line chemotherapy: Paclitaxel Docetaxel If no previous ICI⁸⁾: Nivolumab Pembrolizumab (CPS >10) </p>	<p>JCOG1314 (1st line) CF²⁾ vs. biweekly DCF³⁾ 2014/9~ Follow up period </p>
Recurrent		

1) Esophagectomy+2-3 field lymph node dissection 2) CF: CDDP+5-FU 3) DCF : DOC+CDDP+5-FU 4) CF-RT : CDDP+5-FU+radiation therapy
5) IFI: Involved field irradiation 6) ENI: Elective lymph node irradiation 7) FLOT: 5-FU+LV+OX+DOC 8) ICI: Immune checkpoint inhibitor